Search Results - "Dakhil, S. R."

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer by Socinski, M.A., Langer, C.J., Okamoto, I., Hon, J.K., Hirsh, V., Dakhil, S.R., Page, R.D., Orsini, J., Zhang, H., Renschler, M.F.

“…This analysis evaluates safety and efficacy in elderly (≥70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer…”
Get full text

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer by Socinski, M.A., Okamoto, I., Hon, J.K., Hirsh, V., Dakhil, S.R., Page, R.D., Orsini, J., Yamamoto, N., Zhang, H., Renschler, M.F.

“…This analysis compared the efficacy and safety outcomes by histology of nab-paclitaxel (nab-P) plus carboplatin (C) versus solvent-based paclitaxel (sb-P) plus…”
Get full text

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422) by Jatoi, A., Schild, S.E., Foster, N., Henning, G.T., Dornfeld, K.J., Flynn, P.J., Fitch, T.R., Dakhil, S.R., Rowland, K.M., Stella, P.J., Soori, G.S., Adjei, A.A.

“…Background: Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in…”
Get full text

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study by West, H. L., Crowley, J. J., Vance, R. B., Franklin, W. A., Livingston, R. B., Dakhil, S. R., Giguere, J. K., Rivkin, S. E., Kraut, M., Chansky, K., Gandara, D. R.

“…Background:: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer…”
Get full text

Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2 by BARTON, Debra L, HESHAN LIU, LOPRINZI, Charles L, DAKHIL, Shaker R, LINQUIST, Breanna, SLOAN, Jeff A, NICHOLS, Craig R, MCGINN, Travis W, STELLA, Philip J, SEEGER, Grant R, SOOD, Amit

“…Safe, effective interventions to improve cancer-related fatigue (CRF) are needed because it remains a prevalent, distressing, and activity-limiting symptom…”
Get full text

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group by Giordano, K.F., Jatoi, A., Stella, P.J., Foster, N., Tschetter, L.K., Alberts, S.R., Dakhil, S.R., Mailliard, J.A., Flynn, P.J., Nikcevich, D.A.

“…Background: Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic…”
Get full text

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study by Owonikoko, T.K., Kim, H.R., Govindan, R., Ready, N., Reck, M., Peters, S., Dakhil, S.R., Navarro, A., Rodriguez-Cid, J., Schenker, M., Lee, J.S., Gutierrez, V., Percent, I., Morgensztern, D., Fairchild, J., Baudelet, C., Park, K.

Get full text

Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature by Dakhil, Christopher S. R., Wick, Jo A., Kumar, Anup Kasi Loknath, Satyan, Megha Teeka, Neupane, Prakash

“…Though extrapulmonary small cell carcinoma was first described over 80 years ago, definitive treatment recommendations are lacking. The treatment strategies…”
Get full text

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial by Kim, Edward S., Velcheti, Vamsidhar, Mekhail, Tarek, Yun, Cindy, Shagan, Sarah M., Hu, Sylvia, Chae, Young Kwang, Leal, Ticiana A., Dowell, Jonathan E., Tsai, Michaela L., Dakhil, Christopher S. R., Stella, Philip, Jin, Yanling, Shames, David S., Schleifman, Erica, Fabrizio, David A., Phan, See, Socinski, Mark A.

“…Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies…”
Get full text

Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706 by HUSSEIN, M. A, GUNDACKER, H, HEAD, D. R, ELIAS, L, FOON, K. A, BOLDT, D. H, DOBIN, S. M, DAKHIL, S. R, BUDD, G. T, APPELBAUM, F. R

“…B-cell chronic lymphocytic leukemia (CLL) accounts for 95% of chronic leukemia cases and 25% of all leukemia. Despite the prevalence of CLL, progress in its…”
Get full text

Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603) by Leon-Ferre, Roberto A, Novotny, Paul J, Wolfe, Eric G, Faubion, Stephanie S, Ruddy, Kathryn J, Flora, Daniel, Dakhil, Christopher S R, Rowland, Kendrith M, Graham, Mark L, Le-Lindqwister, Nguyet, Smith, Thomas J, Loprinzi, Charles L

“…Hot flashes (HFs) negatively affect quality of life among perimenopausal and postmenopausal women. This study investigated the efficacy of oxybutynin vs…”
Get full text

Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix by KUDELKA, A. P, WINN, R, FUEGER, R, KAVANAGH, J. J, EDWARDS, C. L, DOWNEY, G, GREENBERG, H, DAKHIL, S. R, FREEDMAN, R. S, LOYER, E, RUSINKIEWICZ, J, GACRAMA, P

“…Twenty-six patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel, 250 mg/m2 over 3 h every 21 days. They received steroid, H1 and…”
Get full text

Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508) by Patel, Jyoti D., Lee, Ju-Whei, Carbone, David P., Wagner, Henry, Shanker, Anil, de Aquino, Maria Teresa P., Horn, Leora, Johnson, Melissa L., Gerber, David E., Liu, Jane Jijun, Das, Millie S., Al-Nsour, Mohammed Ali, Dakhil, Christopher S.R., Ramalingam, Suresh, Schiller, Joan H.

“…Although chemoradiotherapy (CRT) is the standard of care for patients with unresectable stage III non–small-cell lung cancer (LA-NSCLC), most patients relapse…”
Get full text

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix by Kudelka, A P, Winn, R, Edwards, C L, Downey, G, Greenberg, H, Dakhil, S R, Freedman, R S, LoCoco, S, Umbreit, J, Delmore, J E, Arbuck, S, Loyer, E, Gacrama, P, Fueger, R, Kavanagh, J J

“…Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received…”
Get more information

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma by PAZDUR, R, MEDGYESY, D. C, WINN, R. J, DAKHIL, S. R, MOORE, D. F, SCALZO, A, HOFF, P. M, ARBUCK, S. G, ABBRUZZESE, J. L

Get full text

Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma by HOFF, Paulo M, ELLERTON, John A, DAKHIL, S. R, WINN, Rodger J, ABBRUZZESE, James L, PAZDUR, Richard

“…In a multicenter, phase II trial, CI-958, a benzothiopyranoindazole DNA intercalator, was administered to 18 patients who had not received prior chemotherapy…”
Get full text

Association of immune parameters with clinical outcome in stage III colon cancer : results of Southwest Oncology Group Protocol 9009 by HOLCOMBE, R. F, JACOBSON, J, DAKHIL, S. R, STEWART, R. M, BETZING, K. S, KANNAN, K, MACDONALD, J. S

“…Levamisole (LMS), utilized in the adjuvant treatment of patients with stage III colon cancer, is immunomodulatory. To determine whether alterations in immune…”
Get full text

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study by Owonikoko, T K, Kim, H R, Govindan, R, Ready, N, Reck, M, Peters, S, Dakhil, S R, Navarro, A, Rodriguez-Cid, J, Schenker, M, Lee, J S, Gutierrez, V, Percent, I, Morgensztern, D, Fairchild, J, Baudelet, C, Park, K

Get full text

Sequential Biochemical Modulation of Fluorouracil With Folinic Acid, N-Phosphonacetyl-L-Aspartic Acid, and Interferon Alfa-2a in Advanced Colorectal Cancer by ROYCE, M. E, MCGARRY, W, BREADY, B, DAKHIL, S. R, BELT, R. J, GOODWIN, J. W, GRAY, R, HOFF, P. M, WINN, R, PAZDUR, R

“…Several agents have been evaluated for their effect as biochemical modulators of fluorouracil (5-FU) in the treatment of metastatic colorectal carcinoma. In…”
Get full text

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial by Johansson, Harriet, Gray, Kathryn P, Pagani, Olivia, Regan, Meredith M, Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf, Colleoni, Marco, Rabaglio, Manuela, Price, Karen N, Coates, Alan S, Gelber, Richard D, Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A

“…Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have been associated with breast cancer risk,…”
Get full text